These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21912334)

  • 1. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
    Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
    Zhong JS; Meng FY; Xu D; Dai M; Wei YQ; Zhou HS
    Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(30):2120-3. PubMed ID: 22093988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
    Faber E; Friedecký D; Mičová K; Rožmanová S; Divoká M; Jarošová M; Indrák K; Adam T
    Ann Hematol; 2012 Jun; 91(6):923-9. PubMed ID: 22231281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
    Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
    Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug plasma monitoring in CML and GIST: A case-based discussion.
    Egorin MJ; Mauro MJ; Trent JC
    Clin Adv Hematol Oncol; 2009 Nov; 7(11):S1, S3-11. PubMed ID: 20099379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
    Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
    J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of an hollow fiber solid phase microextraction method for the analysis of unbound fraction of imatinib and N-desmethyl imatinib in human plasma.
    Dong WC; Song MY; Zheng TL; Zhang ZQ; Jiang Y; Guo JL; Zhang YZ
    J Pharm Biomed Anal; 2024 Nov; 250():116405. PubMed ID: 39151298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
    Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
    Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison.
    Awidi A; Salem II; Najib N; Mefleh R; Tarawneh B
    Leuk Res; 2010 Jun; 34(6):714-7. PubMed ID: 19744707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
    Iqbal Z; Elliott M; Watson DG; Holyoake T; Jørgensen H
    Pak J Pharm Sci; 2011 Jul; 24(3):285-91. PubMed ID: 21715261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
    Gandia P; Arellano C; Lafont T; Huguet F; Malard L; Chatelut E
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):531-6. PubMed ID: 23183914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method.
    Arellano C; Gandia P; Lafont T; Jongejan R; Chatelut E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Oct; 907():94-100. PubMed ID: 23000741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
    Roth O; Spreux-Varoquaux O; Bouchet S; Rousselot P; Castaigne S; Rigaudeau S; Raggueneau V; Therond P; Devillier P; Molimard M; Maneglier B
    Clin Chim Acta; 2010 Feb; 411(3-4):140-6. PubMed ID: 19853594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of imatinib plasma concentration monitoring in the whole process management of gastrointestinal stromal tumor patients].
    Yang LX; Wang M; Xu RH; Tu L; Zhuang C; Zhao WY; Ma XL; Li M; Zhang J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):841-847. PubMed ID: 31550823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.